128 institutions hold shares in Evofem Biosciences Inc. (EVFM), with 2.1M shares held by insiders accounting for 2.53% while institutional investors hold 34.86% of the company’s shares. The shares outstanding are 81.32M, and float is at 78.84M with Short Float at 11.33%. Institutions hold 33.98% of the Float.
The top institutional shareholder in the company is Invesco Ltd. with over 12.7 million shares valued at $30.61 million. The investor’s holdings represent 15.28% of the EVFM Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 5.21 million shares valued at $12.56 million to account for 6.27% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 3.6 million shares representing 4.33% and valued at over $8.67 million, while Heartland Advisors Inc. holds 3.09% of the shares totaling 2.57 million with a market value of $6.2 million.
Evofem Biosciences Inc. (NASDAQ: EVFM) is -16.18% lower on its value in year-to-date trading and has touched a low of $1.65 and a high of $6.87 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EVFM stock was last observed hovering at around $1.75 in the last trading session, with the day’s gains setting it 0.27% off its average median price target of $6.00 for the next 12 months. It is also 71.14% off the consensus price target high of $7.00 offered by 4 analysts, but current levels are 32.67% higher than the price target low of $3.00 for the same period.
Currently trading at $2.02, the stock is -17.20% and -35.27% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.57 million and changing 15.43% at the moment leaves the stock -27.39% off its SMA200. EVFM registered -60.85% loss for a year compared to 6-month gain of -14.41%. The firm has a 50-day simple moving average (SMA 50) of $3.0624 and a 200-day simple moving average (SMA200) of $2.6768.
The stock witnessed a -43.89% loss in the last 1 month and extending the period to 3 months gives it a -16.87%, and is 18.13% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.51% over the week and 9.54% over the month.
Evofem Biosciences Inc. (EVFM) has around 147 employees, a market worth around $172.41M and $0.40M in sales. Distance from 52-week low is 22.42% and -70.60% from its 52-week high. The company has generated returns on investments over the last 12 months (-131.30%).
Evofem Biosciences Inc. (EVFM) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Evofem Biosciences Inc. (EVFM) is a “Overweight”. 4 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Evofem Biosciences Inc. is expected to release its quarterly report on 08/10/2021 and quarterly earnings per share for the current quarter are estimated at -$0.49 with sales reaching $1.63M over the same period.The EPS is expected to shrink by -6.50% this year, but quarterly earnings will post 5,287.90% year-over-year.
Evofem Biosciences Inc. (EVFM) Insider Activity
A total of 8 insider transactions have happened at Evofem Biosciences Inc. (EVFM) in the last six months, with sales accounting for 0 and purchases happening 8 times. The most recent transaction is an insider purchase by PELLETIER SAUNDRA L, the company’s Chief Executive Officer. SEC filings show that PELLETIER SAUNDRA L bought 45,249 shares of the company’s common stock on Mar 09 at a price of $2.28 per share for a total of $0.1 million. Following the purchase, the insider now owns 0.91 million shares.
Evofem Biosciences Inc. disclosed in a document filed with the SEC on Nov 17 that File Justin J. (Chief Financial Officer) bought a total of 7,760 shares of the company’s common stock. The trade occurred on Nov 17 and was made at $2.17 per share for $16839.0. Following the transaction, the insider now directly holds 0.26 million shares of the EVFM stock.
Still, SEC filings show that on Nov 17, Fitzpatrick Alexander A (General Counsel and Secretary) acquired 9,090 shares at an average price of $2.20 for $19998.0. The insider now directly holds 143,542 shares of Evofem Biosciences Inc. (EVFM).